Mylan NV (NASDAQ : MYL ), a global pharmaceutical company, has launched its Dalfampridine Extended-Release Tablets, 10mg, the authorised generic version of Acorda's Ampyra, in the United States, it was reported on Friday.

The product is indicated to improve walking in adult patients with multiple sclerosis.

The launch comes after the United States Court of Appeals for the Federal Circuit upheld the United States District Court for the District of Delaware's decision to invalidate four Ampyra patents, US Patent Nos 8,663,685, 8,007,826, 8,440,703, and 8,354,437. Acorda's US Patent No 5,540,938, previously upheld by the District Court, expired on 30 July 2018.